Vanda's sleep-disorder drug tasimelteon wins FDA panel support

11/14/2013 | Reuters · American City Business Journals

An FDA advisory panel endorsed the approval of Vanda Pharmaceuticals' tasimelteon as a treatment for non-24-hour sleep-wake disorder in blind people. If approved, the drug would be sold under the brand name Hetlioz. A final decision is expected by Jan. 31.

View Full Article in:

Reuters · American City Business Journals

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY